Restricted accessCase reportFirst published online 2010-1
Therapy-Related Acute Myeloid Leukemia with 11q23 Abnormality Coexisting with Refractory Metastatic Ewing Sarcoma: Report of a Case and Review of the Literature
Intensified chemotherapy is one of the strategies currently used in the treatment of children with metastatic Ewing sarcoma. However, the increasing dose intensity has not significantly improved the event-free survival. We report a patient who initially presented with localized Ewing sarcoma and later developed metastatic disease that required dose-intensified chemotherapy. The patient's Ewing sarcoma remained refractory to treatment despite continuous intensified chemotherapy and was complicated by a therapy-related acute myeloid leukemia with 11q23 abnormality. Examination of bone marrow at the last clinical follow up demonstrated both acute myeloid leukemia and residual metastatic Ewing sarcoma.
Rodriguez-GalindoCLiuTKrasinMJ. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital Studies. Cancer2007;110:375–384.
2.
MiserJSGoldsbyREChenZ. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy. A report from the Children's Oncology Group. Pediatr Blood Cancer2007;49:894–900.
3.
BhatiaSKrailoMDChenZ. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group. Blood2007;109:46–51.
4.
FoucarKMcKennaRWBloomfieldCDBowersTKBrunningRD. Therapy-related leukemia: a panmyelosis. Cancer1979;43:1285–1296.
5.
RowleyJDGolombHMVardimanJW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood1981;58:759–767.
6.
Le BeauMMAlbainKSLarsonRA. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol1986;4:325–345.
7.
Pedesen-BjergaardJRowleyJD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood1994;83:2780–2786.
8.
SmithSMLe BeauMMHuoD. Clinical-cytogenetic association in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood2003;102:43–52.
9.
ColemanCNWilliamsCJFlintA. Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med1977;297:1249–1252.
10.
ReimerRRHooverRFraumeniJFJrYoungRC. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med1977;297:177–181.
11.
ZarrabiMHRosenerFBennettJM. Non-Hodgkin's lymphoma and acute myeloblastic leukemia: a report of 12 cases and review of the literature. Cancer1979;44:1070–1080.
12.
Pedersen-BjergaardJPedersenMRoulstonDPhilipP. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood1995;86:3542–3552.
13.
VardimanJWArberDABrunningRD. Therapy-related myeloid neoplasms. In: SwerdlowSHCampoEHarrisNL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARP Press, 2008;127–129.
14.
GuillemaVTormoM. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma2008;49:204–217.
15.
StrisselPLStrickRRowleyJDZeleznik-LeNJ. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood1998;92:3793–3803.
